Pharmaceutical Products. Outpatient Pharmaceutical Products, including injectable drugs, and New Pharmaceutical Product, for Covered Health Care Services administered on an outpatient basis in a Hospital, Alternate Facility, Physician's office, or in your home. Benefits are provided for Pharmaceutical Products which, due to their traits (as determined by us), are administered or directly supervised by a qualified provider or licensed/certified health professional. Depending on where the Pharmaceutical Product is administered, Benefits will be provided for administration of the Pharmaceutical Product under the corresponding Benefit category in this Policy. Benefits for medication normally available by a prescription or order or refill are provided as described under Section 10: Outpatient Prescription Drugs. If you require certain Pharmaceutical Products, including specialty Pharmaceutical Products, we may direct you to a Designated Dispensing Entity. Such Dispensing Entities may include an outpatient pharmacy, specialty pharmacy, Home Health Agency provider, Hospital-affiliated pharmacy or hemophilia treatment center contracted pharmacy. If you/your provider are directed to a Designated Dispensing Entity and you/your provider choose not to get your Pharmaceutical Product from a Designated Dispensing Entity, Benefits are not available for that Pharmaceutical Product, unless the provider or its intermediary agrees in writing to accept reimbursement, including copayment, at the same rate as a Designated Dispensing Entity. Certain Pharmaceutical Products are subject to step therapy requirements. This means that in order to receive Benefits for such Pharmaceutical Products, you must use a different Pharmaceutical Product and/or prescription drug product first. You may find out whether a particular Pharmaceutical Product is subject to step therapy requirements by contacting us at xxx.xxxxx.xxx/xxxxxxxx or the telephone number on your ID card. A step therapy requirement may not be imposed if: • The step therapy drug has not been approved by the U.S. Food and Drug Administration (FDA) for the medical condition being treated; or • The prescribing provider provides supporting medical information to us that a Prescription Drug Product: ▪ Was ordered by a prescribing provider for the Covered Person within the past 180 days; and ▪ Based on the professional judgment of the prescribing provider, was effective in treating the Covered Person’s medical condition. • The prescription drug has been ap...
Pharmaceutical Products. 2. (a) If a Party requires, as a condition for approving the marketing of a pharmaceutical product that utilizes a new chemical entity, the submission of undisclosed test or other data necessary to determine whether the use of such products is safe and effective, the Party shall protect against disclosure of the data of persons making such submissions, where the origination of such data involves considerable effort, except where the disclosure is necessary to protect the public or unless steps are taken to ensure that the data are protected against unfair commercial use.
Pharmaceutical Products. 30.01 A change to heading 30.01 from any other heading.
Pharmaceutical Products. A change to 30.01-30.05 heading totalled 30.01 to 30.05 from any other heading; or It does not require a change in tariff classification heading to totalled 30.01 to 30.05, complying with a regional value content requirement according to Article 4.2. A change to 3006.10-3006.40 subheading 3006.10 to 3006.40 from any other heading; or there is a change in tariff classification at the subheading 3006.10 to 3006.40, complying with a regional value content requirement according to Article 4.2. 3006.50 provided that qualifies as originating in accordance with article 4.11. a change to 3006.60-3006.91 subheading 3006.60 to 3006.70 from any other heading; or there is a change in tariff classification at the subheading 3006.60 to 3006.91, complying with a regional value content requirement according to Article 4.2. It does not require 3006.92 tariff classification change to subheading 3006.80 provided that waste and scrap are wholly obtained or produced entirely in the territory of a Party as defined in article 4.26. Article 31. Fertilizers 31.01-31.05 heading to a change to 31.02 31.05 from any other heading; or It does not require a change in tariff classification heading to 31.02 to 31.05, complying with a regional value content requirement according to Article 4.2.
Pharmaceutical Products. Emergent shall perform the 3PL Services for the Products that are defined in ARTICLE I of the Agreement (for purposes of this Schedule E, Vials of the Products shall be referred to as the “3PL Vials”).
Pharmaceutical Products. Pharmaceutical products and supplies shall be reimbursed based on National Drug Codes (“NDC codes”), excluding the noted exceptions. The Plan will update The Plan’s NDC fee schedule monthly with the price that is in effect at the time of the update. If ASP is unavailable, pharmaceutical products categorized as Exception will be reimbursed as Single Source or Multi Source. When ASP, WAC, MAC and AWP are unavailable, pharmaceutical products categorized as: Exception, Vaccines and Immunizations, Single Source and/or Multi Source will be reimbursed in accordance with The Plan’s NDC fee schedule in effect as of the date of service.
Pharmaceutical Products. (a) Schedule 4.25(a) lists each product currently developed, manufactured, licensed, distributed or sold by the Company or any Company Subsidiary (collectively, the "Products"). Each Product manufactured by the Company or any Company Subsidiary has been manufactured in accordance with (i) the product registration applicable to such Product, and (ii) the specifications under which the Product is normally and has normally been manufactured.
Pharmaceutical Products. Prescription drug products according to a Department approved formulary, which includes both legend and over-the-counter (OTC) products. The Contractor’s formulary shall include all therapeutic classes in DSHS’ fee-for-service drug file and a sufficient variety of drugs in each therapeutic class to meet enrollees’ medically necessary health care needs. The Contractor shall provide participating pharmacies and participating providers with its formulary and information about how to request non-formulary drugs. The Contractor shall have policies and procedures for the administration of the pharmacy benefit including formulary exceptions. The Contractor shall approve or deny all requests for non-formulary drugs by the business day following the day of request. Covered drug products shall include:
Pharmaceutical Products. This Chapter shall not apply until 1 January of the ninth year of the entry into force of this Additional Protocol, to drug purchases made by the Ministry of Health, IMSS, ISSSTE, the Department of National Defence and the Ministry of the Navy that are not currently patented in Mexico or whose Mexican patents have expired. Nothing in this paragraph shall prejudice the protection of intellectual property rights.
Pharmaceutical Products. The phrase “Pharmaceutical Products” means (i) articles recognized in the official United States Pharmacopoeia, official Homoeopathic Pharmacopoeia of the United States, or official National Formulary, or any supplement to any of them; (ii) articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals; (iii) articles (other than food) intended to affect the structure or any function of the body of man or other animals; (iv) articles classified as a “drug” or “device” under the United States Food, Drug, and Cosmetic Act, 21 U.S.C. § 301, etc., and the regulations promulgated pursuant to such Act; (v) articles classified as a “drug”, “device”, or similar such terms under applicable state or local statutes, ordinances, rules and regulations governing pharmacists or pharmacies; (vi) articles that are dispensed or delivered for administration to or use by a patient or other individual entitled to receive the article pursuant to a prescription issued by a physician, dentist, veterinarian, scientific investigator or other person who has a license to issue such a prescription; and (vii) articles commonly called prescription drugs or prescription medicine.
